Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1880-4233
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population ; day:8 ; month:2 ; year:2019 ; pages:1-7
Breast cancer ; (8.2.2019), 1-7
- Creator
-
Noda-Narita, Shoko
Shimomura, Akihiko
Kawachi, Asuka
Sumiyoshi-Okuma, Hitomi
Sudo, Kazuki
Shimoi, Tatsunori
Noguchi, Emi
Yonemori, Kan
Shimizu, Chikako
Fujiwara, Yasuhiro
Tamura, Kenji
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s12282-019-00949-4
- URN
-
urn:nbn:de:101:1-2019031015583880580753
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:55 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Noda-Narita, Shoko
- Shimomura, Akihiko
- Kawachi, Asuka
- Sumiyoshi-Okuma, Hitomi
- Sudo, Kazuki
- Shimoi, Tatsunori
- Noguchi, Emi
- Yonemori, Kan
- Shimizu, Chikako
- Fujiwara, Yasuhiro
- Tamura, Kenji
- SpringerLink (Online service)
Other Objects (12)
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab
Pertuzumab/Trastuzumab (Mammakarzinom, adjuvant) : Nutzenbewertung gemäß § 35a SGB V
Pertuzumab/Trastuzumab (Mammakarzinom, neoadjuvant) : Nutzenbewertung gemäß § 35a SGB V
Einsatz von Pertuzumab und Trastuzumab im Vergleich zu Trastuzumab-Monotherapie beim HER2-positiven Mammakarzinom - eine multizentrische Kohortenstudie
Characterization of infections and hypogammaglobulinemia treated with the combination of pertuzumab and trastuzumab
Combination efficacy of pertuzumab and trastuzumab for trastuzumab emtansine-resistant cells exhibiting attenuated lysosomal trafficking or efflux pumps upregulation
Pruritus related to trastuzumab and pertuzumab in HER2 + breast cancer patients
Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1)
Arzneimittel Profil Trastuzumab-Deruxtecan
Arzneimittel Profil Trastuzumab-Deruxtecan
Severe hypoglycemia with trastuzumab: An unseen adverse event
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab
Pertuzumab/Trastuzumab (Mammakarzinom, adjuvant) : Nutzenbewertung gemäß § 35a SGB V
Pertuzumab/Trastuzumab (Mammakarzinom, neoadjuvant) : Nutzenbewertung gemäß § 35a SGB V
Einsatz von Pertuzumab und Trastuzumab im Vergleich zu Trastuzumab-Monotherapie beim HER2-positiven Mammakarzinom - eine multizentrische Kohortenstudie
Characterization of infections and hypogammaglobulinemia treated with the combination of pertuzumab and trastuzumab
Combination efficacy of pertuzumab and trastuzumab for trastuzumab emtansine-resistant cells exhibiting attenuated lysosomal trafficking or efflux pumps upregulation
Pruritus related to trastuzumab and pertuzumab in HER2 + breast cancer patients
Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1)
Arzneimittel Profil Trastuzumab-Deruxtecan
Arzneimittel Profil Trastuzumab-Deruxtecan
Severe hypoglycemia with trastuzumab: An unseen adverse event
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab
Pertuzumab/Trastuzumab (Mammakarzinom, adjuvant) : Nutzenbewertung gemäß § 35a SGB V
Pertuzumab/Trastuzumab (Mammakarzinom, neoadjuvant) : Nutzenbewertung gemäß § 35a SGB V
Einsatz von Pertuzumab und Trastuzumab im Vergleich zu Trastuzumab-Monotherapie beim HER2-positiven Mammakarzinom - eine multizentrische Kohortenstudie
Characterization of infections and hypogammaglobulinemia treated with the combination of pertuzumab and trastuzumab
Combination efficacy of pertuzumab and trastuzumab for trastuzumab emtansine-resistant cells exhibiting attenuated lysosomal trafficking or efflux pumps upregulation
Pruritus related to trastuzumab and pertuzumab in HER2 + breast cancer patients
Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1)
Arzneimittel Profil Trastuzumab-Deruxtecan
Arzneimittel Profil Trastuzumab-Deruxtecan